Pharmaceutical News

RSS

Vertellus announces new 3-cyanopyridine production unit at Nantong facility

Vertellus Specialties Inc. announced today that it will break ground on a new 3-cyanopyridine production unit at Vertellus' production facility in Nantong, Jiangsu, China. This unit is a continuation of a larger effort to expand production capacity in Nantong. It will increase Vertellus' Vitamin B3 manufacturing capacity in the region by 10,000 metric tons. The capacity increase will enable Vertellus to maintain its position as the world's second largest provider of Vitamin B3 and the largest producer of cyanopyridines in the world.

8 Jun 2010

APP's lyophilized Oxaliplatin for Injection receives FDA marketing approval

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today it received approval from the U.S. Food and Drug Administration to market Oxaliplatin for Injection (lyophilized), 50 mg and 100 mg.

8 Jun 2010

Can-Fite BioPharma opens CF101 IND for psoriasis with US FDA

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened Investigational New Drug application (IND) with the United States Food and Drug Administration (US FDA). The IND is for Can-Fite's lead compound, CF101, for the treatment of patients with psoriasis. This is the third US IND for CF101, and the fourth for Can-Fite.

8 Jun 2010

Hospira signs licensing agreement to develop and market DURECT's POSIDUR

Hospira, Inc., a global specialty pharmaceutical and medication delivery company, and DURECT Corporation, a specialty pharmaceutical company, today announced that the companies have entered into a licensing agreement to develop and market DURECT's POSIDUR (SABER-bupivacaine) a long-acting version of the anesthetic bupivacaine currently in Phase III clinical trials.

8 Jun 2010

Acella Pharmaceuticals signs license agreement for marketing rights to generic broad-spectrum antibiotic

Acella Pharmaceuticals has signed a licensing agreement for the U.S. marketing rights to a generic version of an intravenous administered broad-spectrum antibiotic.

8 Jun 2010

FDA accepts Depomed's DM-1796 NDA for pain after shingles

Depomed, Inc. today announced that the New Drug Application (NDA) for DM-1796 was accepted by the U.S. Food and Drug Administration (FDA) for the management of postherpetic neuralgia (PHN), or pain after shingles. DM-1796 is an investigational, extended release, once-daily tablet formulation of gabapentin designed to reduce dosing frequency and have a low incidence of side effects.

8 Jun 2010

Targeted therapy that benefits patients with metastatic colon cancer fails to help patients with stage III cancer

To the surprise of researchers at Mayo Clinic who led a national clinical trial, a targeted therapy that provides benefit to patients with metastatic colon cancer has failed to help patients with less advanced, stage III cancer. In fact, patients who used the agent, cetuximab, with chemotherapy had outcomes slightly inferior to patients treated with chemotherapy alone.

7 Jun 2010

Elsevier, InfoDesk partner to co-develop federated drug pipeline intelligence solution

Elsevier, a world-leading healthcare and scientific publisher, announced today that it has reached an agreement with Tarrytown, New York based InfoDesk to co-develop a federated drug pipeline intelligence solution for pharmaceutical and life science companies. The combination of Elsevier's business intelligence expertise and InfoDesk's technological know-how paves the way for the development of a powerful search and delivery tool that will increase productivity and improve the quality of results, securely inside or outside of a customer's firewall.

7 Jun 2010

CytRx granted U.S. Patent for bafetinib

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the granting by the U.S. Patent and Trademark Office (USPTO) of U.S. Patent 7,728,131 for oncology drug candidate bafetinib, encompassing claims related to bafetinib's pharmaceutical compound and composition in all indications, as well as for use in methods for treating acute and chronic myelogenous leukemia and acute lymphoblastic leukemia.

7 Jun 2010

PTC receives $5.4M SDD Award to support development of drugs that target Bmi-1

PTC Therapeutics, Inc. today announced the receipt of a $5.4 million Seeding Drug Discovery Award from The Wellcome Trust to support the development of drugs that target Bmi-1, a protein that has been linked to drug resistant cancers.

7 Jun 2010

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

BioSante Pharmaceuticals, Inc. today announced the receipt of Orphan Drug designation for GVAX CML Vaccine in the treatment of chronic myeloid leukemia (CML) from the FDA's Office of Orphan Products Development. Orphan drug designation, as granted by the U.S. Orphan Drug Act, is for a product to treat a rare disease or condition that affects fewer than 200,000 people in the U.S. Orphan drug designation qualifies the sponsor of the product for tax credits and seven years of marketing exclusivity, among other benefits.

7 Jun 2010

Ranibizumab improves vision in patients with visual impairment due to DME: RESTORE study

Results from a new major diabetes eye health study may have the potential to change the way vision loss due to diabetic macular edema, a serious and devastating complication of diabetes, is treated. One year results from the RESTORE study show that 37 per cent of patients treated with ranibizumab only and 43 per cent of those treated with ranibizumab plus laser therapy, had a significant improvement in visual acuity of 10 letters or more on an eye chart, compared to 16 per cent of patients treated with laser alone - the current standard treatment for visual impairment due to DME.

7 Jun 2010

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating that VB-201 regulates inflammatory pathways, suggesting that it may effectively control inflammatory responses associated with autoimmune diseases and atherosclerosis.

7 Jun 2010

GSK submits BENLYSTA MAA for systemic lupus erythematosus

Human Genome Sciences, Inc. today announced that GlaxoSmithKline (GSK) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval to market BENLYSTA® (belimumab) for the treatment of systemic lupus erythematosus (SLE).

7 Jun 2010

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented preliminary data that shows nitrogen-containing bisphosphonates, therapeutic agents used to promote bone health and inhibit resorption, may cause a slightly poorer survival rate in post-menopausal women with early stage breast cancer who take them for their anti-osteoporosis properties.

7 Jun 2010

MSKCC researchers study novel approach to treat metastatic melanoma

Physician-scientists at Memorial Sloan-Kettering Cancer Center are studying a novel approach to treat metastatic melanoma, known as immunotherapy, which uses the body's own immune system to attack cancer. Presented today at the American Society of Clinical Oncology annual meeting, encouraging new data shows - for the first time - a survival benefit in metastatic melanoma patients using an immunotherapy discovered and clinically investigated by researchers at Memorial Sloan-Kettering.

7 Jun 2010

Raydiance, Rofin partner to offer femtosecond laser technology for manufacture of medical devices

Raydiance, Inc., the innovation leader in ultrafast laser technology, announced today that it is teaming up with Rofin, world-leading manufacturer of laser sources and laser-based solutions for industrial materials processing, to introduce femtosecond laser technology to industrial production.

7 Jun 2010

Grifols to acquire Talecris Biotherapeutics

Grifols a global healthcare company and leading producer of plasma protein therapies, and Talecris a U.S.-based biotherapeutics products company, today announced that they have signed a definitive agreement through which Grifols will acquire Talecris for a combination of cash and newly-issued Grifols non-voting shares having an aggregate value today of approximately $3.4 billion (euro 2.8 billion), creating a global leader of life-saving and life enhancing plasma protein therapeutics.

7 Jun 2010

TABS Group estimates U.S. Vitamin, Minerals and Supplements market at $11B

TABS Group, Inc., a leading marketing research and consulting company based in Shelton, CT, has released their latest estimate of the size of the Vitamin, Minerals and Supplements (VMS) market in the U.S. According to Dr. Kurt Jetta, President of TABS Group, the market has surged by about 20% since the last time an estimate was done in January 2008.

7 Jun 2010

Selenium not beneficial in reducing risk of lung cancer development

Selenium, a supplement taken daily by millions in hopes of protection against cancer and a host of other diseases, has proven to be of no benefit in reducing a patient's risk of developing lung cancer - either a recurrence or second primary malignancy, according to results of an international Phase III clinical trial.

7 Jun 2010

Pharmaceutical News

Vertellus announces new 3-cyanopyridine production unit at Nantong facility

APP's lyophilized Oxaliplatin for Injection receives FDA marketing approval

Can-Fite BioPharma opens CF101 IND for psoriasis with US FDA

Hospira signs licensing agreement to develop and market DURECT's POSIDUR

Acella Pharmaceuticals signs license agreement for marketing rights to generic broad-spectrum antibiotic

FDA accepts Depomed's DM-1796 NDA for pain after shingles

Targeted therapy that benefits patients with metastatic colon cancer fails to help patients with stage III cancer

Elsevier, InfoDesk partner to co-develop federated drug pipeline intelligence solution

CytRx granted U.S. Patent for bafetinib

PTC receives $5.4M SDD Award to support development of drugs that target Bmi-1

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

Ranibizumab improves vision in patients with visual impairment due to DME: RESTORE study

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

GSK submits BENLYSTA MAA for systemic lupus erythematosus

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

MSKCC researchers study novel approach to treat metastatic melanoma

Raydiance, Rofin partner to offer femtosecond laser technology for manufacture of medical devices

Grifols to acquire Talecris Biotherapeutics

TABS Group estimates U.S. Vitamin, Minerals and Supplements market at $11B

Selenium not beneficial in reducing risk of lung cancer development

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News